Enanta Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Equivalents	37.44	32.3	37.23	85.39	43.99	57.21
Short-Term Investments	148.41	156.57	210.95	284.52	205.24	186.8
Cash & Short-Term Investments	185.85	188.86	248.19	369.91	249.23	244
Cash Growth	-14.23%	-23.90%	-32.91%	48.42%	2.14%	-36.89%
Accounts Receivable	8.49	6.88	6.65	8.61	20.32	23.58
Other Receivables	-	-	32	31	28.72	37.26
Receivables	8.49	6.88	38.65	39.62	49.04	60.83
Prepaid Expenses	4.34	8.59	12.41	13.26	13.45	14.19
Restricted Cash	-	-	0.61	-	-	-
Total Current Assets	198.68	204.34	299.85	422.79	311.71	319.02
Property, Plant & Equipment	71.31	72.94	73.35	34.71	29.75	10.65
Long-Term Investments	56.06	-	-	-	29.29	108.42
Other Long-Term Assets	3.45	3.45	3.45	4.77	4.66	0.7
Total Assets	329.5	280.73	376.65	462.28	375.41	438.79
Accounts Payable	1.89	1.95	8	4.1	6	9.54
Accrued Expenses	7.58	12.75	13.55	18.34	20.94	22.43
Current Portion of Long-Term Debt	31.98	30.71	34.46	35.08	-	-
Current Portion of Leases	3.29	3.15	1.52	5.28	2.89	4.2
Total Current Liabilities	44.73	48.56	57.54	62.79	29.83	36.17
Long-Term Debt	104.13	112.44	136.13	160.85	1.42	1.51
Long-Term Leases	53.78	54.76	53.94	21.24	22.37	1.13
Other Long-Term Liabilities	0.27	0.26	0.23	0.66	0.45	0.56
Total Liabilities	202.91	216.02	247.84	245.54	54.08	39.36
Common Stock	0.29	0.21	0.21	0.21	0.21	0.2
Additional Paid-In Capital	543.5	469.77	451.34	424.69	398.03	351.03
Retained Earnings	-416.87	-404.93	-323.04	-207	-73.18	48.58
Comprehensive Income & Other	-0.33	-0.34	0.3	-1.17	-3.72	-0.38
Shareholders' Equity	126.59	64.72	128.81	216.74	321.33	399.43
Total Liabilities & Equity	329.5	280.73	376.65	462.28	375.41	438.79
Total Debt	193.18	201.06	226.06	222.44	26.69	6.84
Net Cash (Debt)	48.72	-12.19	22.13	147.47	251.83	345.58
Net Cash Growth	-	-	-85.00%	-41.44%	-27.13%	-15.65%
Net Cash Per Share	2.10	-0.57	1.05	7.03	12.22	17.13
Filing Date Shares Outstanding	29.02	28.86	21.19	21.06	20.8	20.32
Total Common Shares Outstanding	29.02	21.39	21.19	21.06	20.79	20.24
Working Capital	153.96	155.78	242.32	360	281.89	282.85
Book Value Per Share	4.36	3.03	6.08	10.29	15.46	19.74
Tangible Book Value	126.59	64.72	128.81	216.74	321.33	399.43
Tangible Book Value Per Share	4.36	3.03	6.08	10.29	15.46	19.74
Machinery	-	20.39	19.92	19.14	16.79	16.32
Construction In Progress	-	-	22.75	1.27	2.56	0.02
Leasehold Improvements	-	38.2	13.98	13.8	7.28	7.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.